A UK company has a catalogue of intermediates which can be used for the design & synthesis of novel compounds and offer a variety of customised commercial frameworks. They seeking partners to acquire these compounds and can supply them to researchers or companies in large amounts with a relatively short lead-time. They are seeking service or acquisition agreements with pharmaceutical or drug development companies/researchers interested in using these intermediates for new co-developed products.
The intermediates catalogue provides access to a wide variety of practical building blocks, many of which are unique to the company. The UK company supply all of these compounds in research quantities from stock, while the company's kilo lab facility offers many of these intermediates in 100g-1kg lots with lead times of only 4-6 weeks. In addition to the company's in-house developments, and in order to drive diversity and novelty in their customers' drug discovery programmes, the company fosters strategic collaborations that add new ranges to the intermediates catalogue. They are seeking pharmaceutical and drug development companies and/or researchers for acquisition agreements or services agreements, to supply these products to new partners and co-develop new intermediates with new clients. For example, a previous collaboration with a catalyst technology company resulted in the development of a series of spirodiamine compounds. Such spirodiamines have been shown to be useful in the construction of novel pharmaceutically relevant investigative compounds. The company also offers a variety of customised commercial frameworks, from simple fee-for-service right through to long-term FTE (full-time equivalent) projects. They are trusted by major pharma & biotech companies and operate an embedded team of FTE scientists inside the client's facility on a long-term basis. The company has a significant array of assets for small molecule discovery and has all the essential hardware for modern organic and computational chemistry, a purpose-built ADMET (absorption, distribution, metabolism, excretion and toxicity) lab with cell culture facilities, scale-up laboratories, automated purification to support array synthesis and a highly engineered suite for pressure chemistry. They are also available to offer their services towards any existing H2020 bids that might be relevant.
Innovations and advantages
The intermediates catalogue provides a large variety of practical building blocks, many of which are unique to the company. They can be supplied in research quantities from stock, while the kilo lab facility allows the company to offer many of these intermediates in 100g-1kg lots with lead times of 4-6 weeks. The company was founded in 1992 and is now considered a leading CRO (contract research organisation) in the UK. Using its heritage in the supply of rational building blocks for medicinal chemistry, biased screening libraries and custom synthesis as a springboard, the company now operates a comprehensive suite of services for hit-to-lead and lead optimisation studies. The company's workforce consists of over 85% PhD-level scientists, and the company has a purpose-built lab with cell culture facilities, scale-up laboratories with vessels up to 50L, automated purification to support array synthesis and a highly engineered suite for pressure chemistry.
Market application codes
05007002 Pharmaceuticals/fine chemicals
05007007 Other medical/health related (not elsewhere classified)
Type of partner sought
Type of partner: Industry/academia Activity of partner: Drug development Role of partner in this offer: The co-development of novel pharmaceutical products from the intermediates, which can be used to design and synthesise novel compounds, or the acquisition of intermediates for use.